ML348 is a selective inhibitor of the deubiquitinating enzyme USP25, making it a valuable tool compound in biochemical and cellular research. It is primarily used to study the role of USP25 in various cellular processes, including protein degradation, inflammation, and immune signaling. By inhibiting USP25, ML348 modulates the ubiquitin-proteasome system, which can affect the stability of key regulatory proteins involved in cancer progression and inflammatory diseases. Researchers use ML348 to explore therapeutic strategies targeting deubiquitinases, especially in models of triple-negative breast cancer and viral infection, where USP25 activity influences disease outcomes. Its application helps elucidate the functional impact of USP25 inhibition on NF-κB signaling and cytokine production, supporting the development of targeted therapies.